Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2023

The global Monoclonal Antibody for Multiple Myeloma market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Monoclonal Antibody for Multiple Myeloma is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Monoclonal Antibody for Multiple Myeloma in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Monoclonal Antibody for Multiple Myeloma include Bristol Myers Squibb, Abbvie, Janssen Biotech, Karyopharm Therapeutics, PDL BioPharma, Roche and Seattle Genetics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Multiple Myeloma.

The Monoclonal Antibody for Multiple Myeloma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Monoclonal Antibody for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Monoclonal Antibody for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Bristol Myers Squibb

Abbvie

Janssen Biotech

Karyopharm Therapeutics

PDL BioPharma

Roche

Seattle Genetics

Elotuzumab

Daratumumab

Siltuximab

Dacetuzumab

Rituximab

Other

Hospital

Drug Center

Clinic

Other

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Monoclonal Antibody for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Elotuzumab

1.2.3 Daratumumab

1.2.4 Siltuximab

1.2.5 Dacetuzumab

1.2.6 Rituximab

1.2.7 Other

1.3 Market by Application

1.3.1 Global Monoclonal Antibody for Multiple Myeloma Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Drug Center

1.3.4 Clinic

1.3.5 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Monoclonal Antibody for Multiple Myeloma Market Perspective (2018-2029)

2.2 Monoclonal Antibody for Multiple Myeloma Growth Trends by Region

2.2.1 Global Monoclonal Antibody for Multiple Myeloma Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Monoclonal Antibody for Multiple Myeloma Historic Market Size by Region (2018-2023)

2.2.3 Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Region (2024-2029)

2.3 Monoclonal Antibody for Multiple Myeloma Market Dynamics

2.3.1 Monoclonal Antibody for Multiple Myeloma Industry Trends

2.3.2 Monoclonal Antibody for Multiple Myeloma Market Drivers

2.3.3 Monoclonal Antibody for Multiple Myeloma Market Challenges

2.3.4 Monoclonal Antibody for Multiple Myeloma Market Restraints

3.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Revenue

3.1.1 Global Top Monoclonal Antibody for Multiple Myeloma Players by Revenue (2018-2023)

3.1.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Players (2018-2023)

3.2 Global Monoclonal Antibody for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Monoclonal Antibody for Multiple Myeloma Revenue

3.4 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio

3.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Monoclonal Antibody for Multiple Myeloma Revenue in 2022

3.5 Monoclonal Antibody for Multiple Myeloma Key Players Head office and Area Served

3.6 Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service

3.7 Date of Enter into Monoclonal Antibody for Multiple Myeloma Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Monoclonal Antibody for Multiple Myeloma Historic Market Size by Type (2018-2023)

4.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Type (2024-2029)

5.1 Global Monoclonal Antibody for Multiple Myeloma Historic Market Size by Application (2018-2023)

5.2 Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Application (2024-2029)

6.1 North America Monoclonal Antibody for Multiple Myeloma Market Size (2018-2029)

6.2 North America Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023)

6.4 North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Monoclonal Antibody for Multiple Myeloma Market Size (2018-2029)

7.2 Europe Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023)

7.4 Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size (2018-2029)

8.2 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2018-2023)

8.4 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Monoclonal Antibody for Multiple Myeloma Market Size (2018-2029)

9.2 Latin America Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023)

9.4 Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size (2018-2029)

10.2 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023)

10.4 Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Bristol Myers Squibb

11.1.1 Bristol Myers Squibb Company Detail

11.1.2 Bristol Myers Squibb Business Overview

11.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Introduction

11.1.4 Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.1.5 Bristol Myers Squibb Recent Development

11.2 Abbvie

11.2.1 Abbvie Company Detail

11.2.2 Abbvie Business Overview

11.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Introduction

11.2.4 Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.2.5 Abbvie Recent Development

11.3 Janssen Biotech

11.3.1 Janssen Biotech Company Detail

11.3.2 Janssen Biotech Business Overview

11.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Introduction

11.3.4 Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.3.5 Janssen Biotech Recent Development

11.4 Karyopharm Therapeutics

11.4.1 Karyopharm Therapeutics Company Detail

11.4.2 Karyopharm Therapeutics Business Overview

11.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Introduction

11.4.4 Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.4.5 Karyopharm Therapeutics Recent Development

11.5 PDL BioPharma

11.5.1 PDL BioPharma Company Detail

11.5.2 PDL BioPharma Business Overview

11.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Introduction

11.5.4 PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.5.5 PDL BioPharma Recent Development

11.6 Roche

11.6.1 Roche Company Detail

11.6.2 Roche Business Overview

11.6.3 Roche Monoclonal Antibody for Multiple Myeloma Introduction

11.6.4 Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.6.5 Roche Recent Development

11.7 Seattle Genetics

11.7.1 Seattle Genetics Company Detail

11.7.2 Seattle Genetics Business Overview

11.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Introduction

11.7.4 Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

11.7.5 Seattle Genetics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Elotuzumab

    Table 3. Key Players of Daratumumab

    Table 4. Key Players of Siltuximab

    Table 5. Key Players of Dacetuzumab

    Table 6. Key Players of Rituximab

    Table 7. Key Players of Other

    Table 8. Global Monoclonal Antibody for Multiple Myeloma Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Monoclonal Antibody for Multiple Myeloma Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 10. Global Monoclonal Antibody for Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)

    Table 11. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region (2018-2023)

    Table 12. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 13. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region (2024-2029)

    Table 14. Monoclonal Antibody for Multiple Myeloma Market Trends

    Table 15. Monoclonal Antibody for Multiple Myeloma Market Drivers

    Table 16. Monoclonal Antibody for Multiple Myeloma Market Challenges

    Table 17. Monoclonal Antibody for Multiple Myeloma Market Restraints

    Table 18. Global Monoclonal Antibody for Multiple Myeloma Revenue by Players (2018-2023) & (US$ Million)

    Table 19. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players (2018-2023)

    Table 20. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2022)

    Table 21. Ranking of Global Top Monoclonal Antibody for Multiple Myeloma Companies by Revenue (US$ Million) in 2022

    Table 22. Global 5 Largest Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue (CR5 and HHI) & (2018-2023)

    Table 23. Key Players Headquarters and Area Served

    Table 24. Key Players Monoclonal Antibody for Multiple Myeloma Product Solution and Service

    Table 25. Date of Enter into Monoclonal Antibody for Multiple Myeloma Market

    Table 26. Mergers & Acquisitions, Expansion Plans

    Table 27. Global Monoclonal Antibody for Multiple Myeloma Market Size by Type (2018-2023) & (US$ Million)

    Table 28. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type (2018-2023)

    Table 29. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 30. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Type (2024-2029)

    Table 31. Global Monoclonal Antibody for Multiple Myeloma Market Size by Application (2018-2023) & (US$ Million)

    Table 32. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2018-2023)

    Table 33. Global Monoclonal Antibody for Multiple Myeloma Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 34. Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2024-2029)

    Table 35. North America Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)

    Table 37. North America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Europe Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)

    Table 40. Europe Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029) & (US$ Million)

    Table 41. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2018-2023) & (US$ Million)

    Table 43. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size by Region (2024-2029) & (US$ Million)

    Table 44. Latin America Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Latin America Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 48. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size by Country (2024-2029) & (US$ Million)

    Table 50. Bristol Myers Squibb Company Detail

    Table 51. Bristol Myers Squibb Business Overview

    Table 52. Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Product

    Table 53. Bristol Myers Squibb Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 54. Bristol Myers Squibb Recent Development

    Table 55. Abbvie Company Detail

    Table 56. Abbvie Business Overview

    Table 57. Abbvie Monoclonal Antibody for Multiple Myeloma Product

    Table 58. Abbvie Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 59. Abbvie Recent Development

    Table 60. Janssen Biotech Company Detail

    Table 61. Janssen Biotech Business Overview

    Table 62. Janssen Biotech Monoclonal Antibody for Multiple Myeloma Product

    Table 63. Janssen Biotech Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 64. Janssen Biotech Recent Development

    Table 65. Karyopharm Therapeutics Company Detail

    Table 66. Karyopharm Therapeutics Business Overview

    Table 67. Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Product

    Table 68. Karyopharm Therapeutics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 69. Karyopharm Therapeutics Recent Development

    Table 70. PDL BioPharma Company Detail

    Table 71. PDL BioPharma Business Overview

    Table 72. PDL BioPharma Monoclonal Antibody for Multiple Myeloma Product

    Table 73. PDL BioPharma Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 74. PDL BioPharma Recent Development

    Table 75. Roche Company Detail

    Table 76. Roche Business Overview

    Table 77. Roche Monoclonal Antibody for Multiple Myeloma Product

    Table 78. Roche Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 79. Roche Recent Development

    Table 80. Seattle Genetics Company Detail

    Table 81. Seattle Genetics Business Overview

    Table 82. Seattle Genetics Monoclonal Antibody for Multiple Myeloma Product

    Table 83. Seattle Genetics Revenue in Monoclonal Antibody for Multiple Myeloma Business (2018-2023) & (US$ Million)

    Table 84. Seattle Genetics Recent Development

    Table 85. Research Programs/Design for This Report

    Table 86. Key Data Information from Secondary Sources

    Table 87. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Monoclonal Antibody for Multiple Myeloma Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Monoclonal Antibody for Multiple Myeloma Market Share by Type: 2022 VS 2029

    Figure 3. Elotuzumab Features

    Figure 4. Daratumumab Features

    Figure 5. Siltuximab Features

    Figure 6. Dacetuzumab Features

    Figure 7. Rituximab Features

    Figure 8. Other Features

    Figure 9. Global Monoclonal Antibody for Multiple Myeloma Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 10. Global Monoclonal Antibody for Multiple Myeloma Market Share by Application: 2022 VS 2029

    Figure 11. Hospital Case Studies

    Figure 12. Drug Center Case Studies

    Figure 13. Clinic Case Studies

    Figure 14. Other Case Studies

    Figure 15. Monoclonal Antibody for Multiple Myeloma Report Years Considered

    Figure 16. Global Monoclonal Antibody for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 17. Global Monoclonal Antibody for Multiple Myeloma Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 18. Global Monoclonal Antibody for Multiple Myeloma Market Share by Region: 2022 VS 2029

    Figure 19. Global Monoclonal Antibody for Multiple Myeloma Market Share by Players in 2022

    Figure 20. Global Top Monoclonal Antibody for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Multiple Myeloma as of 2022)

    Figure 21. The Top 10 and 5 Players Market Share by Monoclonal Antibody for Multiple Myeloma Revenue in 2022

    Figure 22. North America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. North America Monoclonal Antibody for Multiple Myeloma Market Share by Country (2018-2029)

    Figure 24. United States Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Canada Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Europe Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Europe Monoclonal Antibody for Multiple Myeloma Market Share by Country (2018-2029)

    Figure 28. Germany Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. France Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. U.K. Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Italy Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Russia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Nordic Countries Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Asia-Pacific Monoclonal Antibody for Multiple Myeloma Market Share by Region (2018-2029)

    Figure 36. China Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Japan Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. South Korea Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Southeast Asia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. India Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Australia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Latin America Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Latin America Monoclonal Antibody for Multiple Myeloma Market Share by Country (2018-2029)

    Figure 44. Mexico Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Brazil Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Middle East & Africa Monoclonal Antibody for Multiple Myeloma Market Share by Country (2018-2029)

    Figure 48. Turkey Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 49. Saudi Arabia Monoclonal Antibody for Multiple Myeloma Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 50. Bristol Myers Squibb Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 51. Abbvie Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 52. Janssen Biotech Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 53. Karyopharm Therapeutics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 54. PDL BioPharma Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 55. Roche Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 56. Seattle Genetics Revenue Growth Rate in Monoclonal Antibody for Multiple Myeloma Business (2018-2023)

    Figure 57. Bottom-up and Top-down Approaches for This Report

    Figure 58. Data Triangulation

    Figure 59. Key Executives Interviewed